Real-world effectiveness of simnotrelvir-ritonavir versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19 during the omicron wave in China: a retrospective cohort study

DOI record: { "DOI": "10.1186/s12879-025-11195-9", "ISSN": [ "1471-2334" ], "URL": "http://dx.doi.org/10.1186/s12879-025-11195-9", "alternative-id": [ "11195" ], "article-number": "840", "assertion": [ { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Received", "name": "received", "order": 1, "value": "12 March 2025" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Accepted", "name": "accepted", "order": 2, "value": "2 June 2025" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "First Online", "name": "first_online", "order": 3, "value": "1 July 2025" }, { "group": { "label": "Declarations", "name": "EthicsHeading" }, "name": "Ethics", "order": 1 }, { "group": { "label": "Ethics approval and consent to participate", "name": "EthicsHeading" }, "name": "Ethics", "order": 2, "value": "This study was conducted in accordance with the ethical principles outlined in the Declaration of Helsinki. Verbal informed consent was obtained from all participants in this study through telephone follow-up procedures. Approval of Clinical Research by the Ethics Committee of the First Affiliated Hospital of Kunming Medical University[(2024 L)No. 75]." }, { "group": { "label": "Consent for publication", "name": "EthicsHeading" }, "name": "Ethics", "order": 3, "value": "Not applicable." }, { "group": { "label": "Competing interests", "name": "EthicsHeading" }, "name": "Ethics", "order": 4, "value": "The authors declare no competing interests." } ], "author": [ { "affiliation": [], "family": "Li", "given": "Chuntao", "sequence": "first" }, { "affiliation": [], "family": "Cheng", "given": "Qingzhao", "sequence": "additional" }, { "affiliation": [], "family": "Chen", "given": "Ying", "sequence": "additional" }, { "affiliation": [], "family": "Liu", "given": "Ling", "sequence": "additional" }, { "affiliation": [], "family": "Liu", "given": "Dajin", "sequence": "additional" }, { "affiliation": [], "family": "Zhang", "given": "Jiaqiang", "sequence": "additional" }, { "affiliation": [], "family": "Liao", "given": "Zehua", "sequence": "additional" }, { "affiliation": [], "family": "Xiang", "given": "Yaling", "sequence": "additional" }, { "affiliation": [], "family": "Zhou", "given": "Jinbiao", "sequence": "additional" }, { "affiliation": [], "family": "Liao", "given": "Keke", "sequence": "additional" }, { "affiliation": [], "family": "Su", "given": "Yandi", "sequence": "additional" }, { "affiliation": [], "family": "Zhang", "given": "Xuemei", "sequence": "additional" }, { "affiliation": [], "family": "Li", "given": "Jiashu", "sequence": "additional" }, { "affiliation": [], "family": "Zhao", "given": "Yuping", "sequence": "additional" }, { "affiliation": [], "family": "Yang", "given": "Yue", "sequence": "additional" }, { "affiliation": [], "family": "Zhang", "given": "Jianqing", "sequence": "additional" }, { "affiliation": [], "family": "Yang", "given": "Long", "sequence": "additional" } ], "container-title": "BMC Infectious Diseases", "container-title-short": "BMC Infect Dis", "content-domain": { "crossmark-restriction": false, "domain": [ "link.springer.com" ] }, "created": { "date-parts": [ [ 2025, 7, 1 ] ], "date-time": "2025-07-01T10:29:35Z", "timestamp": 1751365775000 }, "deposited": { "date-parts": [ [ 2025, 7, 1 ] ], "date-time": "2025-07-01T10:29:38Z", "timestamp": 1751365778000 }, "funder": [ { "award": [ "no. 202401AYO70001-239" ], "name": "2024 Yunnan Provincial Science and Technology Department-Kunming Medical University Joint Basic Research Program, China" }, { "award": [ "no. L2019007" ], "name": "Medical Leaders Training Program of Yunnan Provincial Health Commission" } ], "indexed": { "date-parts": [ [ 2025, 7, 2 ] ], "date-time": "2025-07-02T04:10:27Z", "timestamp": 1751429427478, "version": "3.41.0" }, "is-referenced-by-count": 0, "issue": "1", "issued": { "date-parts": [ [ 2025, 7, 1 ] ] }, "journal-issue": { "issue": "1", "published-online": { "date-parts": [ [ 2025, 12 ] ] } }, "language": "en", "license": [ { "URL": "https://creativecommons.org/licenses/by-nc-nd/4.0", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2025, 7, 1 ] ], "date-time": "2025-07-01T00:00:00Z", "timestamp": 1751328000000 } }, { "URL": "https://creativecommons.org/licenses/by-nc-nd/4.0", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2025, 7, 1 ] ], "date-time": "2025-07-01T00:00:00Z", "timestamp": 1751328000000 } } ], "link": [ { "URL": "https://link.springer.com/content/pdf/10.1186/s12879-025-11195-9.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://link.springer.com/article/10.1186/s12879-025-11195-9/fulltext.html", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://link.springer.com/content/pdf/10.1186/s12879-025-11195-9.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "297", "original-title": [], "prefix": "10.1186", "published": { "date-parts": [ [ 2025, 7, 1 ] ] }, "published-online": { "date-parts": [ [ 2025, 7, 1 ] ] }, "publisher": "Springer Science and Business Media LLC", "reference": [ { "key": "11195_CR1", "unstructured": "World Health Organization (WHO). Number of COVID-19 cases reported to WHO. 2024. Available from: https://data.who.int/dashboards/covid19/cases?n=c. Cited 2025 May 3." }, { "key": "11195_CR2", "unstructured": "Centers for Disease Control and Prevention (CDC). SARS-CoV-2 variant classifications anddefinitions. 2023. Available from: https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-classifications.html. Cited 2025 May 3." }, { "key": "11195_CR3", "unstructured": "Global Initiative on Sharing All Influenza Data (GISAID). Phylodynamics of pandemic coronavirus across the globe. 2024. Available from: https://gisaid.org/phylodynamics/global/nextstrain. Cited 2025 May 3." }, { "key": "11195_CR4", "unstructured": "Chinese Center for Disease Control and Prevention (China CDC). COVID-19 vaccination status. 2022. Available from: https://www.chinacdc.cn/jkzt/crb/zl/szkb_11803/jszl_12208/202212/t20221225_263105.html. Cited 2025 May 3." }, { "key": "11195_CR5", "unstructured": "World Health Organization (WHO). Therapeutics and COVID-19: living guideline. 2023. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2023.2. Cited 2025 May 3." }, { "DOI": "10.1056/NEJMc2402378", "author": "P Selvi-Sabater", "doi-asserted-by": "publisher", "first-page": "1534", "issue": "16", "journal-title": "N Engl J Med", "key": "11195_CR6", "unstructured": "Selvi-Sabater P, de la RubiaOrtí JE, Urbieta-Sanz E. Oral simnotrelvir for adult patients with mild-to-moderate covid-19. N Engl J Med. 2024;390(16):1534. https://doi.org/10.1056/NEJMc2402378.", "volume": "390", "year": "2024" }, { "DOI": "10.1080/14656566.2024.2323597", "author": "MW McCarthy", "doi-asserted-by": "publisher", "first-page": "233", "issue": "3", "journal-title": "Expert Opin Pharmacother", "key": "11195_CR7", "unstructured": "McCarthy MW. Simnotrelvir as a potential treatment for COVID-19. Expert Opin Pharmacother. 2024;25(3):233–7. https://doi.org/10.1080/14656566.2024.2323597.", "volume": "25", "year": "2024" }, { "DOI": "10.1002/med.21783", "author": "M Xiong", "doi-asserted-by": "publisher", "first-page": "1965", "issue": "4", "journal-title": "Med Res Rev", "key": "11195_CR8", "unstructured": "Xiong M, Su H, Zhao W, Xie H, Shao Q, Xu Y. What coronavirus 3C-like protease tells us: from structure, substrate selectivity, to inhibitor design. Med Res Rev. 2021;41(4):1965–98. https://doi.org/10.1002/med.21783.", "volume": "41", "year": "2021" }, { "DOI": "10.1128/jvi.02013-21", "author": "J Li", "doi-asserted-by": "publisher", "first-page": "e0201321", "issue": "8", "journal-title": "J Virol", "key": "11195_CR9", "unstructured": "Li J, Lin C, Zhou X, Zhong F, Zeng P, Yang Y, Zhang Y, Yu B, Fan X, McCormick PJ, Fu R, Fu Y, Jiang H, Zhang J. Structural basis of the main proteases of coronavirus bound to drug candidate PF-07321332. J Virol. 2022;96(8):e0201321. https://doi.org/10.1128/jvi.02013-21.", "volume": "96", "year": "2022" }, { "DOI": "10.1124/dmd.121.000801", "author": "H Eng", "doi-asserted-by": "publisher", "first-page": "576", "issue": "5", "journal-title": "Drug Metab Dispos", "key": "11195_CR10", "unstructured": "Eng H, Dantonio AL, Kadar EP, Obach RS, Di L, Lin J, Patel NC, Boras B, Walker GS, Novak JJ, Kimoto E, Singh RSP, Kalgutkar AS. Disposition of nirmatrelvir, an orallybioavailable Inhibitor of SARS-CoV-2 3C-like protease, across animals and humans. Drug Metab Dispos. 2022;50(5):576–90. https://doi.org/10.1124/dmd.121.000801.", "volume": "50", "year": "2022" }, { "DOI": "10.1056/NEJMoa2118542", "author": "J Hammond", "doi-asserted-by": "publisher", "first-page": "1397", "issue": "15", "journal-title": "N Engl J Med", "key": "11195_CR11", "unstructured": "Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, Baniecki M, Hendrick VM, Damle B, Simón-Campos A, Pypstra R, Rusnak JM, EPIC-HR Investigators. Oral nirmatrelvir for high-risk, nonhospitalized adults with covid-19. N Engl J Med. 2022;386(15):1397–408. https://doi.org/10.1056/NEJMoa2118542.", "volume": "386", "year": "2022" }, { "DOI": "10.1056/NEJMoa2309003", "author": "J Hammond", "doi-asserted-by": "publisher", "first-page": "1186", "issue": "13", "journal-title": "N Engl J Med", "key": "11195_CR12", "unstructured": "Hammond J, Fountaine RJ, Yunis C, Fleishaker D, Almas M, Bao W, Wisemandle W, Baniecki ML, Hendrick VM, Kalfov V, Simón-Campos JA, Pypstra R, Rusnak JM. Nirmatrelvir for vaccinated or unvaccinated adult outpatients with covid-19. N Engl J Med. 2024;390(13):1186–95. https://doi.org/10.1056/NEJMoa2309003.", "volume": "390", "year": "2024" }, { "DOI": "10.7326/M22-3057", "author": "EYF Wan", "doi-asserted-by": "publisher", "first-page": "505", "issue": "4", "journal-title": "Ann Intern Med", "key": "11195_CR13", "unstructured": "Wan EYF, Yan VKC, Mok AHY, Wang B, Xu W, Cheng FWT, Lai FTT, Chui CSL, Li X, Wong CKH, Li PH, Cowling BJ, Hung IFN, Lau CS, Wong ICK, Chan EWY. Effectiveness of molnupiravir and nirmatrelvir-ritonavir in hospitalized patients with COVID-19: a target trial emulation study. Ann Intern Med. 2023;176(4):505–14. https://doi.org/10.7326/M22-3057.", "volume": "176", "year": "2023" }, { "DOI": "10.1016/S1473-3099(22)00507-2", "author": "CKH Wong", "doi-asserted-by": "publisher", "first-page": "1681", "issue": "12", "journal-title": "Lancet Infect Dis", "key": "11195_CR14", "unstructured": "Wong CKH, Au ICH, Lau KTK, Lau EHY, Cowling BJ, Leung GM. Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong’s omicron BA.2 wave: a retrospective cohort study. Lancet Infect Dis. 2022;22(12):1681–93. https://doi.org/10.1016/S1473-3099(22)00507-2.", "volume": "22", "year": "2022" }, { "DOI": "10.1016/j.lanwpc.2023.100694", "author": "J Liu", "doi-asserted-by": "publisher", "first-page": "100694", "journal-title": "Lancet Reg Health West Pac", "key": "11195_CR15", "unstructured": "Liu J, Pan X, Zhang S, Li M, Ma K, Fan C, Lv Y, Guan X, Yang Y, Ye X, Deng X, Wang Y, Qin L, Xia Z, Ge Z, Zhou Q, Zhang X, Ling Y, Qi T, Wen Z, Huang S, Zhang L, Wang T, Liu Y, Huang Y, Li W, Du H, Chen Y, Xu Y, Zhao Q, Zhao R, Annane D, Qu J, Chen D. Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study. Lancet Reg Health West Pac. 2023;33:100694. https://doi.org/10.1016/j.lanwpc.2023.100694.", "volume": "33", "year": "2023" }, { "DOI": "10.1016/j.jinf.2023.05.012", "author": "Y Dian", "doi-asserted-by": "publisher", "first-page": "e24", "issue": "2", "journal-title": "J Infect", "key": "11195_CR16", "unstructured": "Dian Y, Meng Y, Sun Y, Deng G, Zeng F. Azvudine versus Paxlovid for oral treatment of COVID-19 in Chinese patients with pre-existing comorbidities. J Infect. 2023;87(2):e24–7. https://doi.org/10.1016/j.jinf.2023.05.012.", "volume": "87", "year": "2023" }, { "DOI": "10.1056/NEJMoa2204919", "author": "R Arbel", "doi-asserted-by": "publisher", "first-page": "790", "issue": "9", "journal-title": "N Engl J Med", "key": "11195_CR17", "unstructured": "Arbel R, Wolff Sagy Y, Hoshen M, Battat E, Lavie G, Sergienko R, Friger M, Waxman JG, Dagan N, Balicer R, Ben-Shlomo Y, Peretz A, Yaron S, Serby D, Hammerman A, Netzer D. Nirmatrelvir use and severe covid-19 outcomes during the omicron surge. N Engl J Med. 2022;387(9):790–8. https://doi.org/10.1056/NEJMoa2204919.", "volume": "387", "year": "2022" }, { "DOI": "10.1038/s41586-022-05514-2", "author": "S Iketani", "doi-asserted-by": "publisher", "first-page": "558", "issue": "7944", "journal-title": "Nature", "key": "11195_CR18", "unstructured": "Iketani S, Mohri H, Culbertson B, Hong SJ, Duan Y, Luck MI, Annavajhala MK, Guo Y, Sheng Z, Uhlemann AC, Goff SP, Sabo Y, Yang H, Chavez A, Ho DD. Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir. Nature. 2023;613(7944):558–64. https://doi.org/10.1038/s41586-022-05514-2.", "volume": "613", "year": "2023" }, { "DOI": "10.1038/s41467-023-42102-y", "author": "X Jiang", "doi-asserted-by": "publisher", "first-page": "6463", "issue": "1", "journal-title": "Nat Commun", "key": "11195_CR19", "unstructured": "Jiang X, Su H, Shang W, Zhou F, Zhang Y, Zhao W, Zhang Q, Xie H, Jiang L, Nie T, Yang F, Xiong M, Huang X, Li M, Chen P, Peng S, Xiao G, Jiang H, Tang R, Zhang L, Shen J, Xu Y. Structure-based development and preclinical evaluation of the SARS-CoV-2 3C-like protease inhibitor simnotrelvir. Nat Commun. 2023;14(1):6463. https://doi.org/10.1038/s41467-023-42102-y.", "volume": "14", "year": "2023" }, { "DOI": "10.1016/j.antiviral.2022.105419", "author": "L Ma", "doi-asserted-by": "publisher", "first-page": "105419", "journal-title": "Antiviral Res", "key": "11195_CR20", "unstructured": "Ma L, Li Q, Xie Y, Zhao J, Yi D, Guo S, Guo F, Wang J, Yang L, Cen S. Repurposing of HIV/HCV protease inhibitors against SARS-CoV-2 3CLpro. Antiviral Res. 2022;207:105419. https://doi.org/10.1016/j.antiviral.2022.105419.", "volume": "207", "year": "2022" }, { "DOI": "10.1159/000521288", "author": "ME Charlson", "doi-asserted-by": "publisher", "first-page": "8", "issue": "1", "journal-title": "Psychother Psychosom", "key": "11195_CR21", "unstructured": "Charlson ME, Carrozzino D, Guidi J, Patierno C. Charlson Comorbidity Index: a critical review of clinimetric properties. Psychother Psychosom. 2022;91(1):8–35. https://doi.org/10.1159/000521288.", "volume": "91", "year": "2022" }, { "key": "11195_CR22", "unstructured": "National Institutes of Health (NIH). COVID-19 treatment guidelines: clinical spectrum of SARS-CoV-2 infection. 2023. Available from: https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum. Cited 2025 May 3." }, { "author": "National Health Commission of the People's Republic of China (NHC)", "first-page": "81", "issue": "15", "journal-title": "Chin J Clin Infect Dis", "key": "11195_CR23", "unstructured": "National Health Commission of the People’s Republic of China (NHC). Diagnosis and treatment plan for COVID-19 (Trial Version 9). Chin J Clin Infect Dis. 2022;2(15):81–9.", "volume": "2", "year": "2022" }, { "author": "National Health Commission of the People’s Republic of China (NHC)", "first-page": "1", "issue": "1", "journal-title": "Chin J Clin Infect Dis", "key": "11195_CR24", "unstructured": "National Health Commission of the People’s Republic of China (NHC). Diagnosis and treatment plan for COVID-19 (Trial Version 10). Chin J Clin Infect Dis. 2023;16(1):1–9.", "volume": "16", "year": "2023" }, { "key": "11195_CR25", "unstructured": "National Medical Products Administration (NMPA). Simnotrelvir tablets/ritonavir tablets (co-packaged) and deuremidevir hydrobromide tablets for treating COVID-19. 2023. Available from: https://english.nmpa.gov.cn/2023-01/29/c_888728.htm. Cited 2025 May 3." }, { "key": "11195_CR26", "unstructured": "World Health Organization (WHO). WHO R&D Blueprint: novel coronavirus COVID-19 therapeutic trial synopsis. 2020. Available from: https://www.who.int/docs/default-source/blue-print/covid-19-therapeutic-trial-synopsis.pdf. Cited 2025 May 3." }, { "DOI": "10.1016/j.cmi.2021.05.022", "author": "E Boehm", "doi-asserted-by": "publisher", "first-page": "1109", "issue": "8", "journal-title": "Clin Microbiol Infect.", "key": "11195_CR27", "unstructured": "Boehm E, Kronig I, Neher RA, Eckerle I, Vetter P, Kaiser L, Geneva Centre for Emerging Viral Diseases. Novel SARS-CoV-2 variants: the pandemics within the pandemic. Clin Microbiol Infect. 2021;27(8):1109–17. https://doi.org/10.1016/j.cmi.2021.05.022.", "volume": "27", "year": "2021" }, { "DOI": "10.1038/s41586-021-04385-3", "author": "Y Cao", "doi-asserted-by": "publisher", "first-page": "657", "issue": "7898", "journal-title": "Nature", "key": "11195_CR28", "unstructured": "Cao Y, Wang J, Jian F, Xiao T, Song W, Yisimayi A, Huang W, Li Q, Wang P, An R, Wang J, Wang Y, Niu X, Yang S, Liang H, Sun H, Li T, Yu Y, Cui Q, Liu S, Yang X, Du S, Zhang Z, Hao X, Shao F, Jin R, Wang X, Xiao J, Wang Y, Xie XS. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature. 2022;602(7898):657–63. https://doi.org/10.1038/s41586-021-04385-3.", "volume": "602", "year": "2022" }, { "DOI": "10.1016/j.cytogfr.2023.03.001", "author": "L Wang", "doi-asserted-by": "publisher", "first-page": "13", "journal-title": "Cytokine Growth Factor Rev", "key": "11195_CR29", "unstructured": "Wang L, Møhlenberg M, Wang P, Zhou H. Immune evasion of neutralizing antibodies by SARS-CoV-2 omicron. Cytokine Growth Factor Rev. 2023;70:13–25. https://doi.org/10.1016/j.cytogfr.2023.03.001. Epub 2023 Mar 5. Erratum in: Cytokine Growth Factor Rev. 2024 Jun;77:117. https://doi.org/10.1016/j.cytogfr.2024.03.006.", "volume": "70", "year": "2023" }, { "key": "11195_CR30", "unstructured": "Chinese Center for Disease Control and Prevention (China CDC). National situation of novel coronavirus infection. 2023. Available from: https://www.chinacdc.cn/jkzt/crb/zl/szkb_11803/. Cited 2025 May 3." }, { "DOI": "10.1002/jmv.28756", "author": "G Deng", "doi-asserted-by": "publisher", "first-page": "e28756", "issue": "4", "journal-title": "J Med Virol", "key": "11195_CR31", "unstructured": "Deng G, Li D, Sun Y, Jin L, Zhou Q, Xiao C, Wu Q, Sun H, Dian Y, Zeng F, Pan P, Shen M. Real-world effectiveness of azvudine versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19: a retrospective cohort study. J Med Virol. 2023;95(4):e28756. https://doi.org/10.1002/jmv.28756.", "volume": "95", "year": "2023" }, { "DOI": "10.1186/s12879-023-08965-8", "author": "X Han", "doi-asserted-by": "publisher", "first-page": "57", "issue": "1", "journal-title": "BMC Infect Dis", "key": "11195_CR32", "unstructured": "Han X, Gao D, Li C, Yuan X, Cui J, Zhao W, Xie F, Wang K, Liu Y, Muo G, Xi N, Zheng M, Wang R, Xiao K, Zhao D, Zhang X, Han X, Wang B, Zhang T, Xie W, Xie L. Real-world effectiveness of nirmatrelvir-ritonavir versus azvudine in hospitalized patients with COVID-19 during the omicron wave in Beijing: a multicenter retrospective cohort study. BMC Infect Dis. 2024;24(1):57. https://doi.org/10.1186/s12879-023-08965-8.", "volume": "24", "year": "2024" }, { "DOI": "10.2147/IDR.S433186", "author": "CY Hu", "doi-asserted-by": "publisher", "first-page": "7797", "issue": "16", "journal-title": "Infect Drug Resist", "key": "11195_CR33", "unstructured": "Hu CY, Cui WS, Lei Y, Tang YW, Zhang YY, Su QM, Peng F, Zeng YF, Song JL, Luo CN, Zhou Y, Li XY, Zhao ZX. Comparison of azvudine and nirmatrelvir/ritonavir and combined use in patients with COVID-19. Infect Drug Resist. 2023;22(16):7797–808. https://doi.org/10.2147/IDR.S433186.", "volume": "22", "year": "2023" }, { "DOI": "10.1016/S0140-6736(22)01586-0", "author": "CKH Wong", "doi-asserted-by": "publisher", "first-page": "1213", "issue": "10359", "journal-title": "Lancet", "key": "11195_CR34", "unstructured": "Wong CKH, Au ICH, Lau KTK, Lau EHY, Cowling BJ, Leung GM. Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study. Lancet. 2022;400(10359):1213–22. https://doi.org/10.1016/S0140-6736(22)01586-0.", "volume": "400", "year": "2022" }, { "DOI": "10.1177/08850666241c228841", "author": "X Chen", "doi-asserted-by": "publisher", "first-page": "742", "issue": "8", "journal-title": "J Intensive Care Med", "key": "11195_CR35", "unstructured": "Chen X, Zhu Y, Shen L, Zhou D, Feng N, Tong Q. Efficacy and safety of nirmatrelvir/ritonavir in severe hospitalized patients with COVID-19 and in patients at high risk for progression to critial illness: a real-world study. J Intensive Care Med. 2024;39(8):742–50. https://doi.org/10.1177/08850666241c228841.", "volume": "39", "year": "2024" } ], "reference-count": 35, "references-count": 35, "relation": {}, "resource": { "primary": { "URL": "https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-025-11195-9" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [], "subtitle": [], "title": "Real-world effectiveness of simnotrelvir-ritonavir versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19 during the omicron wave in China: a retrospective cohort study", "type": "journal-article", "update-policy": "https://doi.org/10.1007/springer_crossmark_policy", "volume": "25" }